Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice.

BACKGROUND Inducible NO synthase (NOS2, or iNOS) is upregulated in grafts with transplant arteriosclerosis. However, the functional role of NOS2 in the pathogenesis of transplant arteriosclerosis remains unclear. NOS2 may regulate lesion development by modulating the early alloimmune response and/or late myointimal thickening. METHODS AND RESULTS To determine whether NOS2-mediated pathways protect against or promote transplant arteriosclerosis, we used NOS2-deficient mice as recipients in our vascularized chronic cardiac rejection model. The severity of vascular thickening in 55-day grafts placed into NOS2 -/- recipients (n=13) was compared with that in wild-type recipients (n=15). Computer-assisted analysis of all elastin-stained vessels (n=283) showed significantly increased luminal occlusion (77.11+/-9.4% versus 40.8+/-13.6%, P<.0001) and intima/media ratios in allografts from NOS2 -/- recipients (1.9+/-1.3 versus 0.4+/-0.3, P=.0002). To elucidate potential mechanisms, we studied NOS2 effects on T-cell differentiation (Th1/Th2) and neointimal smooth muscle cell accumulation. Normalized mRNA levels for Th1- (signal transducer and activator of transcription [STAT] 4, interleukin [IL]-2, interferon-gamma) and Th2- (STAT 6, IL-4, and IL-5) associated factors were comparable in both groups. In contrast, quantitative analysis of the alpha-actin-positive area showed a significant increase in the contribution of smooth muscle cells within the neointima in allografts from NOS2 -/- recipients (28.2+/-2.0%) compared with wild-type controls (13.2+/-2.3%; P<.0001). CONCLUSIONS NOS2 plays a protective role in the development of transplant arteriosclerosis, suppressing neointimal smooth muscle cell accumulation.

[1]  M. Russell,et al.  Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. , 1998, The American journal of pathology.

[2]  M. Russell,et al.  Sustained anti-CD4/CD8 treatment blocks inflammatory activation and intimal thickening in mouse heart allografts. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[3]  R. Brandes,et al.  Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. , 1997, Circulation.

[4]  G. Hansson,et al.  Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. , 1996, The American journal of pathology.

[5]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[6]  R. Starling,et al.  Morphometric and immunocytochemical analysis of coronary arterioles in human transplanted hearts. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  R. Novick,et al.  The Registry of the International Society for Heart and Lung Transplantation: thirteenth official report--1996. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[9]  R. Sarkar,et al.  Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. , 1996, Circulation research.

[10]  M. Sayegh,et al.  Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. , 1996, The Journal of clinical investigation.

[11]  J. Loscalzo,et al.  Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. , 1995, The Journal of clinical investigation.

[12]  S M Schwartz,et al.  The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.

[13]  J. Seki,et al.  FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. , 1995, Atherosclerosis.

[14]  J. Loscalzo,et al.  Nitric oxide and its role in the cardiovascular system. , 1995, Progress in cardiovascular diseases.

[15]  M. Karnovsky,et al.  Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. , 1995, Circulation.

[16]  M. Lewis,et al.  The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. , 1995, Cardiovascular research.

[17]  D. Taub,et al.  Murine Th1 and Th2 cell clones differentially regulate macrophage nitric oxide production , 1995, Journal of leukocyte biology.

[18]  R. Michler,et al.  Effects of immunosuppressive therapy on expression of inducible nitric oxide synthase (iNOS) during cardiac allograft rejection. , 1995, International journal of cardiology.

[19]  I. Charles,et al.  Altered immune responses in mice lacking inducible nitric oxide synthase , 1995, Nature.

[20]  C. Nathan,et al.  Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase , 1995, Cell.

[21]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. P. Misko,et al.  Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase , 1995, The Journal of experimental medicine.

[23]  E. Arnold,et al.  Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. , 1994, The American journal of physiology.

[24]  C. Marboe,et al.  Induction of myocardial nitric oxide synthase by cardiac allograft rejection. , 1994, The Journal of clinical investigation.

[25]  A. Taylor-Robinson,et al.  Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells , 1994, European journal of immunology.

[26]  M. Karnovsky,et al.  EXPERIMENTAL GRAFT ARTERIOSCLEROSIS II. IMMUNOCYTOCHEMICAL ANALYSIS OF LESION DEVELOPMENT , 1993, Transplantation.

[27]  S. Moncada,et al.  The role of TH1 and TH2 cells in a rodent malaria infection. , 1993, Science.

[28]  J. R. Lancaster,et al.  Nitric oxide--a new endogenous immunomodulator. , 1993, Transplantation.

[29]  J. Albina,et al.  Nitric oxide-mediated apoptosis in murine peritoneal macrophages. , 1993, Journal of immunology.

[30]  L. Ignarro,et al.  L-arginine inhibits balloon catheter-induced intimal hyperplasia. , 1993, Biochemical and biophysical research communications.

[31]  S. Snyder,et al.  Nitric oxide, a novel biologic messenger , 1992, Cell.

[32]  P. Tsao,et al.  Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. , 1992, The Journal of clinical investigation.

[33]  M. Salter,et al.  A possible novel pathway of regulation by murine T helper type‐2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages , 1991, European journal of immunology.

[34]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  U. Garg,et al.  Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. , 1990, Biochemical and biophysical research communications.

[36]  A. Hassid,et al.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.

[37]  L. Ignarro,et al.  Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. , 1981, Blood.

[38]  R. Corry,et al.  PRIMARILY VASCULARIZED ALLOGRAFTS OF HEARTS IN MICE: THE ROLE OF H‐2D, H‐2K, AND NON‐H-2 ANTIGENS IN REJECTION , 1973, Transplantation.

[39]  P. Libby,et al.  Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[40]  P. Libby,et al.  Apoptosis of Vascular Smooth Muscle Cells Induced by In Vitro Stimulation With Interferon-γ, Tumor Necrosis Factor–α, and Interleukin-1β , 1996 .

[41]  F. Liew,et al.  Regulation of lymphocyte functions by nitric oxide. , 1995, Current opinion in immunology.

[42]  C. Orosz,et al.  Transplant vascular sclerosis , 1995 .

[43]  Von der Leyen.  Gene therapy inhibiting neointimal vascular lesion , 1995 .